Experimental human pneumococcal carriage (EHPC) is scientifically important because nasopharyngeal carriage of Streptococcus pneumoniae is both the major source of transmission and the prerequisite of invasive disease. A model of carriage will allow accurate determination of the immunological correlates of protection, the immunizing effect of carriage and the effect of host pressure on the pathogen in the nasopharyngeal niche. Further, methods of carriage detection useful in epidemiologic studies, including vaccine studies, can be compared.
1
. Current conjugate vaccines against pneumococcus protect children from invasive disease although new vaccines are urgently needed as the current vaccine does not confer optimal protection against non-bacteraemic pneumonia and there has been evidence of serotype replacement with non-vaccine serotypes [2] [3] [4] .
Method
We inoculate with S. pneumoniae suspended in 100 μl of saline. Safety is a major factor in the development of the EHPC model and is achieved through intensive volunteer screening and monitoring. A safety committee consisting of clinicians and scientists that are independent from the study provides objective feedback on a weekly basis.
The bacterial inoculum is standardized and requires that no animal products are inoculated into volunteers (vegetable-based media and saline). The doses required for colonization (10 . Detecting pneumococcal carriage is enhanced by a high volume (ideally >10 ml) nasal wash that is relatively mucus free. This protocol will deal with the most important parts of the protocol in turn. These are (a) volunteer selection, (b) pneumococcal inoculum preparation, (c) inoculation, (d) follow-up and (e) carriage detection.
Results
Our current protocol has been safe in over 100 volunteers at a range of doses using two different bacterial serotypes 6 . A dose ranging study using S. pneumoniae 6B and 23F is currently being conducted to determine the optimal inoculation dose for 50% carriage. A predicted 50% rate of carriage will allow the EHPC model to have high sensitivity for vaccine efficacy with small study numbers.
Preparation of Inoculation Stocks
1. Preparation of the inoculation stocks must be done in a clean environment. The pipettes used should only be used for inoculum preparation.
All glass and plastic ware should be sterile. We recommend that inoculation stocks be prepared in a dedicated room, using a dedicated fumehood and incubator. 2. Pneumococcal strains are inoculated onto a blood agar plate. Plates are incubated at 37 °C in 5% CO 2 overnight. The following day all the bacteria is scraped from the blood agar plate and inoculated into a bead stock preservation system. These bead stocks are used for inoculation stock preparation. Test the bead stocks for contamination and colony uniformity before preparing an inoculation stock. 3. To prepare the inoculation stock, inoculate a blood agar plate with two beads from the desired pneumococcal serotype bead stock, streaking to cover the entire plate. Incubate plates at 37 °C in 5% CO 2 overnight. All further incubations will use these same conditions. Also incubate the Vegitone media overnight to ensure sterility. 4. The next morning swab half the plate, taking care not to remove any blood agar, and add to 12 ml of pre-warmed Vegitone broth. Repeat using the other half of the plate. Leave the two 12 ml vials at 37 °C for 2 hr or until a change in turbidity becomes apparent, whichever comes first. 5. Add the 12 ml to 40 ml of pre-warmed Vegitone broth and mix thoroughly. Repeat for the other 12 ml vial. This is time point = 0. Remove 100 μl to read the optical density (OD) at 600 nm. Remove 20 μl for quantification of bacteria by colony forming unit (CFU) count using a variation of the method by Miles and Misra (M&M) 7 . Incubate both vials. 1. For the M&M, divide a blood agar plate into six sections. Add 180 μl of sterile PBS to six wells of a 96 well plate (U-bottom). Add 20 μl of the broth to the top well and mix. Serially dilute the sample 1:10 six times and discard 20 μl from the sixth well. Place three 10 μl drops from the top well into the first section of the blood agar plate. Repeat for the five other wells. Ensure the plate is dry before it is inverted and incubated. 2. The next day count the number of visible colonies in each dilution section and record. Using the dilution section with a count between 30 and 300, divide the number of visible colonies by three to get an average. 3. Multiply the average number of colonies by the dilution factor and then divide by 10 (the amount of the 10 μl drop). This gives CFU/μl. 4. Multiply this number by 1,000 to get CFU/ml. 6. Perform OD 600 readings and quantification of bacteria by M&M method every hour until early mid-log phase is reached, an OD of 0.25. 7. Once this OD is reached, add sterilized 10% glycerol to one vial and prepare 1 ml aliquots. Store aliquots at -80 °C. 8. For a more concentrated stock, centrifuge the other vial at 3,345 x g for 15 min and remove the supernatant. Resuspend the pellet in 22.5 ml of Vegitone medium and add 10% glycerol. Prepare 1 ml aliquots and store at -80 °C. 9. Leave stocks at -80 °C for at least 48 hr before thawing and quantifying. 10. Quantify the frozen bacterial stock by the M&M method. Test three stock tubes individually to ensure reproducibility. Use the value obtained to dilute the stock to the desired inoculum concentration in saline, as described below. 11. For an inoculation, the quantity of pneumococci in the inoculum is calculated before and after the inoculation. This quantification of bacteria by the M&M method is used to determine the average number of pneumococci in the inoculum which accounts for the time it takes to complete the entire procedure. 1. Prepare an inoculum, diluting to the desired concentration, and perform quantification by the M&M method for the "pre-inoculation" count.
4. Plate a 20 μl drop of the STGG containing the resuspended pellet onto a blood agar plate containing gentamicin and streak the entire plate. 1. If the NW is post-inoculation, remove 10 μl from the STGG containing the resuspended pellet and use for bacterial quantification by M&M method.
5. Add another 800 μl of STGG to the NW tube and mix thoroughly. 6. Plate 25 μl onto a blood agar plate and 25 μl onto a chocolate agar plate, streaking the entire plate. 7. Divide the remaining amount bacteria suspended in STGG medium into 2 cryovials and store at -80 °C. 8. Incubate the plates at 37 °C overnight in 5% CO 2 . 9. Examine the plates the next day for pneumococcus and other potential respiratory pathogens. 10. Pneumococci are identified on plates by colony morphology. Alpha haemolytic colonies with draughtsman morphology are sub-cultured onto blood agar with an optochin disc and incubated overnight. 11. Presumptive pneumococcal colonies that are optochin sensitive are Gram stained to confirm Gram positive diplococci and serotyped using the Statens Serum Institut Pneumotest-Latex kit.
Representative Results
We have experience inoculating 159 people, of which 35 have carried pneumococcus. The lowest dose we achieved carriage with using serotype 6B was 11,100 CFU/100 μl per naris, the highest dose was 313,000 CFU/100 μl per naris. The lowest dose we achieved carriage with using serotype 23F was 9,000 CFU/100 μl per naris, the highest dose was 84,500 CFU/100 μl per naris.
Our method of carriage assessment is a nasal wash, chosen because a recent study 10 showed that 91% of volunteers found nasal wash to be more comfortable than nasopharyngeal swab; the nasal wash was also more likely to detect pathogens using microbiological culture. Microbial flora recovered on blood agar plates inoculated with NW can be variable and difficult to read. Gentamicin is used on the first blood agar plate to select for pneumococcus. The chocolate agar plate and the second blood agar plate are used to detect other potential respiratory pathogens which may help or hinder pneumococcal colonization. An example of a blood agar plate inoculated with NW that is easy to read is shown in Figure 1a ; a difficult plate containing numerous kinds of flora is shown in Figure 1b .
At every appointment volunteers were asked to describe any upper respiratory tract symptoms, if present, and comparisons between carriers and non-carriers were highlighted. Of the 145 people recently inoculated with pneumococcus, 28 complained of symptoms ( Table 1) . Eight of these were carriers, twenty were not. The most common symptoms were non-specific nasal symptoms ( Table 1) . Of the cases in which there were reported systemic symptoms, including fever and/or malaise, none of the investigations undertaken showed evidence of pneumococcal disease and symptoms were consistent with concurrent viral infection except in one case of tonsillitis. Two pneumococcal positive volunteers were treated with antibiotics. One complained of sore throat and ear ache and, after meeting with the study doctor, was advised to take antibiotics as a precaution. The other volunteer was diagnosed clinically with tonsillitis. All volunteers had rapid resolution of symptoms. Blood agar plates inoculated with NW can be difficult to read. 1a is an example of a plate that is easy to read with pneumococci clearly visible. 1b is a plate with lots of co-colonizing flora making it more difficult to detect if pneumococci is present. Table 1 . Characterization of volunteer reported symptoms following S. pneumoniae 6B inoculation. All complaints were reviewed by the external safety committee and, following full investigations, no symptoms were attributed to pneumococcal disease. The most common symptoms were sore throat, stuffed nose and flu-like illness.
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